Ole K. Jeppesen - Publications

Response to Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265.

Journal: Diabetes care

Published: May 20, 2026

Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?

Journal: The Journal of clinical endocrinology and metabolism

Published: April 10, 2026

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.

Journal: JAMA cardiology

Published: March 25, 2026

Effect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: November 06, 2025

Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: October 03, 2025

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.

Journal: Nature medicine

Published: September 19, 2025

Response to "Weight-loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk".

Journal: Obesity (Silver Spring, Md.)

Published: May 19, 2025

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.

Journal: Lancet (London, England)

Published: May 13, 2025

Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.

Journal: Diabetes care

Published: May 08, 2025

Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.

Journal: Obesity (Silver Spring, Md.)

Published: August 13, 2024

Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.

Journal: Diabetes care

Published: April 12, 2024

Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.

Journal: Diabetes care

Published: March 07, 2024